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http://www.trialsjournal.com/content/15/1/49METHODOLOGY Open AccessDeveloping core outcomes sets: methods for
identifying and including patient-reported
outcomes (PROs)
Rhiannon C Macefield1*, Marc Jacobs2, Ida J Korfage3, Joanna Nicklin4, Robert N Whistance1, Sara T Brookes1,
Mirjam AG Sprangers2 and Jane M Blazeby1,4Abstract
Background: Synthesis of patient-reported outcome (PRO) data is hindered by the range of available PRO measures
(PROMs) composed of multiple scales and single items with differing terminology and content. The use of core
outcome sets, an agreed minimum set of outcomes to be measured and reported in all trials of a specific condition,
may improve this issue but methods to select core PRO domains from the many available PROMs are lacking. This
study examines existing PROMs and describes methods to identify health domains to inform the development of a
core outcome set, illustrated with an example.
Methods: Systematic literature searches identified validated PROMs from studies evaluating radical treatment for
oesophageal cancer. PROM scale/single item names were recorded verbatim and the frequency of similar names/
scales documented. PROM contents (scale components/single items) were examined for conceptual meaning by
an expert clinician and methodologist and categorised into health domains. A patient advocate independently
checked this categorisation.
Results: Searches identified 21 generic and disease-specific PROMs containing 116 scales and 32 single items with
94 different verbatim names. Identical names for scales were repeatedly used (for example, ‘physical function’ in six
different measures) and others were similar (overlapping face validity) although component items were not always
comparable. Based on methodological, clinical and patient expertise, 606 individual items were categorised into 32
health domains.
Conclusion: This study outlines a methodology for identifying candidate PRO domains from existing PROMs to
inform a core outcome set to use in clinical trials.
Keywords: Core outcome set, Patient reported outcome (PRO), Patient reported outcome measure (PROM),
Randomised controlled trial (RCT), Trial methodology, Health domains, Quality of life, Systematic reviewBackground
Outcome selection and reporting in randomised con-
trolled trials (RCTs) is often problematic. Heterogeneity
in outcomes measured across studies in the same disease
or treatment may hamper effective evidence synthesis.
A systematic review of oesophageal studies, for example,
found 10 different measures for postoperative mortality
which were often undefined [1]. In addition, selective* Correspondence: r.macefield@bristol.ac.uk
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stated.reporting of outcomes puts trials at risk of outcome
reporting bias and can mean treatment effects are exag-
gerated [2]. These issues may be further complicated for
patient reported outcomes (PROs). PROs are typically
assessed using questionnaires (patient reported outcome
measures (PROMs)) and many validated questionnaires
are available because PROMs have been developed by
different groups and disciplines (for example, clinical
versus psychological) or for differing purposes (for ex-
ample, measurement of health in generic populations
versus disease-specific patient groups). A single PROMral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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and generic and disease specific PROMs are often
combined to assess a range of relevant health domains
within an RCT. This means that different (and often
ill-defined) outcomes may be reported and the multi-
plicity of items and scales may also allow selection of
statistically significant rather than pre-determined a
priori PRO endpoints to be reported, increasing the
risk of outcome reporting bias. Problems are further
accentuated for PROs because terminology of the scales
and items across PROMs is not universally agreed
meaning data synthesis across studies is difficult when
different questionnaires are used, and while there is
overlap in the issues that are measured there is also
variation because PROMs have been developed by dif-
ferent methods and for different purposes. Potential
solutions to these challenges are to develop and use
core outcome sets.
Core outcome sets (COSs) are an agreed minimum set
of outcome domains to be measured and reported in all
trials of a particular treatment or condition [3]. The rou-
tine measurement of COSs has the potential to facilitate
data synthesis and reduce outcome reporting bias by
standardising the outcomes that are measured across
studies and this has been emphasised by the COMET
(Core Outcome Measures in Effectiveness Trials) initia-
tive which supports the development and application of
COSs for pragmatic (effectiveness) trials [4]. Pragmatic
trials are designed to assess whether an intervention is
effective for routine clinical practice and outcomes,
therefore, need to be relevant and important to patients
as well as clinicians and other key decision-makers [5].
In many cases these are the outcomes that are assessed
with PROMs, particularly if the questionnaire has been
developed with patient input [6] but the availability of
so many different PROMs, however, means there are
problems with selecting which of the measured health
domains are ‘core’. The aim of this study, therefore, was
to explore and report methods to identify PRO domains
from the wealth of available PROMs and to use this
approach to inform the development of a COS to use
in pragmatic trials in a specific condition. Consensus
on which outcomes to include in the final core set, and
the methods to achieve this, are the focus of further
research.
Methods
This study was undertaken within one disease site and
treatment - radical treatment for oesophageal cancer,
selected because the research team have clinical and
PROM expertise in this area and have previously tried
to summarise PRO evidence [7-9]. There were three phases
of work: (1) a systematic literature review to identify
validated PROMs used in oesophageal cancer studiesand the scope of these instruments; (2) a detailed content
analysis to explore PROM diversity; and (3) categorisation
of PROM content into health domains (Figure 1).
Identification of PROMs used in oesophageal cancer studies
A systematic review was performed to identify and present
the scope of existing validated PROMs in order to provide
knowledge of the current of state of PRO measurement in
this field.
Search strategy
Electronic searches in MEDLINE, Embase, PsycINFO and
CINAHL databases between January 2006 and May 2011
were performed. The search strategy included terms for
patient-reported outcomes, oesophageal cancer, surgery
and chemotherapy, radiotherapy or combined therapy
(see Additional file 1). Searches were limited to studies
published in English language. Relevant studies published
prior to 2006 were identified from a previous systematic
review [8]. Abstracts of identified records were screened
for inclusion and full text articles were assessed for eli-
gibility by one of three reviewers (RW, MJ, RCM) with
reasons for exclusion documented. No studies were ex-
cluded based on a risk of bias assessment or judgement
of methodological quality because the purpose of the
current study was to identify PROs rather than examine
the quality of the data or treatment effect.
Selection criteria
Included were studies that used at least one validated
PROM to evaluate health-related quality of life (HRQL)
after radical treatment of oesophageal cancer, including
surgical, chemotherapy and/or radiotherapy interventions.
Valid PROMs were defined as those that had been tested
for psychometric validity and reliability in appropriate
patient populations with methodology verified from pub-
lished papers. No restrictions on study design or sample
size were applied. Studies of palliative treatment, compari-
sons of clinician- or hospital-related factors, and those lim-
ited to investigating satisfaction with care or health utilities
were excluded.
Data extraction
Data were extracted using a pre-designed form, piloted
before full data extraction with a sample of included
studies. Study publication date, design and treatment
intervention, the name of the PROM(s), the reported
PRO scales and single items, and details of any additional
non-validated questions were extracted. These were re-
corded by one reviewer (RM) and checked by additional
members of the study team (MJ, MAGS). The validated
PROMs were obtained, including other validated disease-
specific PROMs known to authors. Verbatim names for
the PRO scales and single items as termed by the PROM
Existing scope and knowledge
Phase 1 – Identification of PROMs 
Current diversity 
Framework to inform core outcome set
Systematic search for oesophageal 
cancer studies
List validated PROMs used in studies 
known to authors
Obtain copy of PROM and/or 
development paper describing 
PROM contents and scales
conceptual health domains
List verbatim scales / single items 
Examine scale component items 
Compare scales with similar names
Phase 3 – Categorisation into health domains 
Phase 2 – PROM content analysis 
Categorise all individual items into  
and other disease specific measures 
Figure 1 Methods to identify PRO domains to inform a core outcome set.
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components and any single items) were recorded. Data
were stored in an electronic database.
Examination of PROM content
A detailed content analysis of the identified instruments
was performed to explore the diversity of PROs in this
field. Verbatim names for scales and single items were
listed. Scales with identical names and others that were
similar (defined as having a least one identical word) were
documented, counted and compared for consistency and
overlap of the component items.
Categorisation into health domains
To synthesise the existing content of instruments and
provide a framework for future core set development, all
PROM items (scale components and any single items)
were examined and systematically categorised into con-
ceptual health domains according to the issue they ad-
dressed. This was performed by expert methodologists
(an oesophageal cancer surgeon and a psychologist) with
experience of questionnaire development in health-related
quality of life research and cancer (JMB and MAGS)
based on their knowledge, familiarity and practiced
skill of grouping questionnaire items in this field. Health
domains were defined as generic aspects of quality of life
affected by health or disease-specific issues and symptoms
[10]. Further domains were defined until saturation, that
is, all individual PROM items had been mapped onto adomain. Issues addressed in non-validated questions were
additionally mapped to domains to verify that the concep-
tual health domains encompassed all outcomes measured
in the included studies. Mapping of items to domains was
checked for completeness and consistency by two authors
(IK and RCM) and a patient advocate working within on-
cology research to maximise validity and reliability of the
method. Variances were resolved by discussion within the
study team and with the senior author (JMB). Data were
recorded electronically.Results
Identification of PROMs used in oesophageal cancer studies
A total of 1,351 records were screened for inclusion and
111 full-text articles were assessed for eligibility. Of
these, 56 were excluded because they did not meet the
criteria for eligibility, including seven studies that used
PROMs without sufficient psychometric validation. Some
55 relevant articles reporting 56 studies were identified
(Table 1) [11-65]. Almost all studies (n = 54, 96%) included
data on PROs after surgery, either alone or with neoad-
juvant chemo/radiotherapy. Nineteen validated PROMs
were used (Table 1) [56,66-83]: nine for gastrointestinal
diseases, five cancer-specific instruments and five generic
instruments. One oesophageal specific PROM was adapted
from a cancer instrument (adapted Rotterdam Symp-
tom Checklist). Three were earlier versions of an updated
PROM (EORTC QLQ-C36, QLQ-OES24 and MOS SF20).
The most frequently used PROMs were the EORTC
Table 1 Oesophageal cancer studies (n = 56) using
validated PROMs (n = 21)
n (%)
Study design RCT 4 (7)
Longitudinal 25 (45)
Cross-sectional 27 (48)
Publication year <1995 1 (2)
1995-1999 6 (11)
2000-2004 12 (21)
2005-2009 26 (46)
2010-2011 11 (20)
Primary outcome
Clinical measure (for example,
morbidity, mortality)
2 (4)
PRO (for example, HRQL, symptoms) 40 (7)
Undefined/both clinical & PRO 14 (25)
Studies using
PROM (n)
PROM scales and
single items (n)
PROM QLQ-C30 34 15
QLQ-OES18 19 10
SF36 12 8
QLQ-OES24 8 11
GIQLI 3 5
FACT-E 3 5
Adapted RSCL 4 4/5a
QLQ-C36 2 18
GERD-HRQL 1 2
DAUGS32 1 7
LAGS 1 3
RSCL 1 3
Adapted RSCL 1 5
PNPC 1 9
WOCS 1 1
MOS SF20 1 6
PAIS 1 7
POMS 1 6
HADS 1 2
EQOLb 0 5
QLQ-OG25b 0 16
aOne study used an adapted version with an additional scale [56].
bSourced from authors’ knowledge; PROM yet to be used in a published study
at the time of the conducted search.
DAUGS: Dysfunction After Upper Gastrointestinal Surgery; EQOL: Esophageal
Quality of Life Questionnaire; FACT-E: Functional Assessment of Cancer
Therapy - Esophageal; GERD-HRQL: Gastroesophageal Reflux Disease-Health
Related Quality of Life; GIQLI: Gastrointestinal Quality of Life Index; HADS:
Hospital Anxiety and Depression scale; HRQL: Health-related Quality of Life; LAGS:
Life After Gastric Surgery index; MOS: Medical Outcomes Study; OES:
Oesophageal; OG: Oesophagogastric; PAIS: Psychosocial Adjustment to Iillness
Scale; POMS: Profile of Moods States; PNPC: Problems and Needs in Palliative
Care; QLQ: Quality of Life Qquestionnaire; RCT: Randomised controlled trial; RSCL:
Rotterdam Symptom Checklist; SF36: Short form 36; WOCS: Worry of Cancer scale.
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EORTC QLQ-OES18, or earlier version QLQ-OES24 (n =
27, 48%). PROMs were not always used in their entirety,
with evidence of selective outcome reporting of scales and
single items in 33 (59%), although there was variation
across studies in the outcomes that were selected (data not
shown). Twenty-one (37%) studies added an additional 74
non-validated items. A further two validated disease specific
PROMs; the EORTC QLQ-OG25 [84] and EQOL[85], were
sourced from authors’ knowledge, neither of which had
been used in a published study since development and val-
idation at the time of the conducted search (May 2011).
Examination of PROM content
There were 116 scales (composed from 574 individual
items) and 32 single items in total, with 94 different
verbatim scale/item names (Table 2). ‘Pain’ and ‘physical
function’ were the most common verbatim name for a
scale, used in six different PROMs, but other PROM
scale names were also very similar (for example, physical
wellbeing, physical problems, physical distress, physical
activity, role physical) (Table 3). Some scales with identical
names, however, had different component items. For ex-
ample, ‘physical function’ in one PROM consisted of seven
items relating to tiredness/fatigue, feeling unwell, waking
up at night, changes in appearance, physical strength,
endurance and feeling unfit [72], compared to ‘physical
function’ in another PROM consisting of five items that
referred to strenuous activity, ability to walk certain dis-
tances, time spent in bed or a chair, and need for help
with self-care [74]. Similar heterogeneity was found for
PROs assessed with single items, for example ‘cough’ in
one PROM assessed waking at night because of cough-
ing [67], whereas in another it was an assessment of
coughing following eating [69]. While the two items
assessed slightly different aspects of coughing they had
the same name (‘cough’) and thus reporting would only
refer to cough and not the actual issue being assessed
within the item.
Categorisation into health domains
All PROM individual items (n = 606) were categorised
into 32 conceptual generic or symptom specific domains
by the study authors (Table 4). Illustrative examples of
this categorisation process are provided for some of the
generic health domains (Table 5). The most common
assessed health domain (concept), that is, the health
domain that most PROM items mapped to, was emotional
function, assessed in 18 of the 21 PROMs. Other com-
monly assessed health domains were ‘pain/pain-related
swallowing’ (assessed in 14 different PROMs), ‘physical
activity/activities of daily life’ (in 13 PROMs) and ‘appetite/
eating/taste’ (in 12 PROMs). Uncommon domains were
‘spiritual issues’ (assessed in one PROM) and ‘dizziness/
Table 2 Verbatim names of PROM scales and single items
1 Activities of daily living 33 Extended familyrelationships 65 Professional care providers
2 Activity level 34 Fatigue 66 Psychological symptoms
3 Anger-hostility 35 Fatigue-inertia 67 Psychological distress
4 Anxiety 36 Financial difficulties 68 Psychological impact
5 Appetite loss 37 Financial impact 69 Psychological issues
6 Bodily pain 38 Fullness following meals 70 Reflux
7 Body image 39 Functional wellbeing 71 Role emotional
8 Choking 40 General health 72 Role function
9 Cognitive function 41 Global evaluations 73 Role physical
10 Confusion-bewilderment 42 Global QOL 74 Sexual relationships
11 Constipation 43 Global satisfaction 75 Sleep disturbances
12 Cough 44 Global life satisfaction 76 Social activities
13 Deglutition 45 Hair loss 77 Social environment
14 Deglutition disturbances 46 Health perceptions 78 Social function
15 Depression 47 Healthcare orientation 79 Social issues
16 Depression-dejection 48 Heartburn 80 Social/family wellbeing
17 Diarrhoea 49 Indigestion 81 Speech
18 Diarrhoea/constipation 50 Information needs 82 Spiritual issues
19 Difficulty in swallowing 51 Insomnia 83 Stool formation
20 Domestic environment 52 Loss of independence 84 Swallowing problems
21 Dry mouth 53 Loss of weight 85 Symptoms
22 Dumping 54 Medical treatment 86 Symptoms of GERD
23 Dysphagia 55 Mental health 87 Taste
24 Dyspnoea 56 Nausea & vomiting 88 Tension-anxiety
25 Eating 57 Odynophagia 89 Trouble swallowing saliva
26 Eating restrictions 58 Pain 90 Vigour-activity
27 Eating with others 59 Physical symptoms 91 Vitality
28 Emotion 60 Physical activity 92 Vocational environment
29 Emotional function 61 Physical distress 93 Weight
30 Emotional problems (anxiety) 62 Physical function 94 Worry/fear of recurrence
31 Emotional wellbeing 63 Physical problems
31 Esophageal cancer scale 64 Physical wellbeing
GERD: Gastroesophageal reflux disease; QOL: Quality of life.
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tions predominantly focused on eating and therefore were
mapped onto the ‘appetite/eating/taste’ domain. A patient
advocate checked the categorisation of items into health
domains and there were no difference of opinion.
Discussion
This study comprehensively analysed PROs from studies
in radical treatment for oesophageal cancer. Some 116
scales and 32 single items were identified from 21 vali-
dated PROMs. As many as 94 different verbatim names
were used to describe PRO scales and single items and
although many names were similar, content examinationrevealed component questions did not always address
comparable issues. In-depth examination and categorisa-
tion of PROM contents concluded that together they ad-
dressed 32 different health domains demonstrating the
vast overlap between PROMs.
Our findings show how evidence synthesis of oesophageal
cancer PROs may be hampered because of the range of
PROMs used in trials and the multiple scales and single
items within them, often with inconsistent and non-
transparent terminology. Core outcome sets aim to reduce
this problem by identifying and prioritising the important
health domains to be measured in all studies. The devel-
opment of core outcome sets in other clinical areas has
Table 3 Identical and similar names for PRO scales used
in different PROMs
Scale name PROMs using identical
scale name
Scales with similara
names (origin PROM)
Pain QLQ C30 Bodily pain (SF 36)
QLQ C36
QLQ OES18
QLQ OES24
QLQ OG25
DAUG 32
Physical function MOS SF20 Physical wellbeing (FACT-E)
QLQ C30 Physical problems (PNPC)
QLQ C36 Physical distress (RSCL)
SF 36 Physical activity (DAUG 32)
EQOL Role physical (SF 36)
GIQLI
Social function QLQ C30 Social activities (PNPC)
QLQ C36 Social environment (PAIS)
SF 36 Social issues (PNPC)
EQOL Social/family wellbeing
(FACT-E)
GIQLI
Activities of
daily living
PNPC
EQOL
RSCL
Dysphagia QLQ OES18
QLQ OES24
QLQ OG25
Emotional function QLQ C30 Emotional wellbeing
(FACT-E)
QLQ C36 Emotional problems
(anxiety) (QLQ OES24)
EQOL Emotion (GIQLI)
Role emotional (SF 36)
Global QOL QLQ C30 Global life satisfaction
(LAGS)
QLQ C36
Nausea & Vomiting DAUG 32
QLQ C30
QLQ C36
Psychological
distress
RSCL Psychological issues (PNPC)
RSCL(adapted) Psychological impact
(LAGS)
PAIS Psychological symptoms
(RSCL, adapted)
Reflux DAUG 32
QLQ OG25
QLQ OES18
Table 3 Identical and similar names for PRO scales used
in different PROMs (Continued)
Role function MOS SF20
QLQ C30
QLQ C36
Symptoms GIQLI Physical symptoms
(RSCL, adapted)
LAGS Symptoms of GERD
(GERD-HRQL)
EQOL
Activity level RSCL Vigour-activity (POMS)
RSCL (adapted)
Anxiety QLQ OG25 Tension-anxiety (POMS)
HADS
Cognitive function QLQ C30
QLQ C36
Eating QLQ OES18 Eating restrictions
(QLQ OG25)
QLQ OES24 Eating with others
(QLQ OG25)
Fatigue QLQ C30 Fatigue-Inertia (POMS)
QLQ C36
Mental Health MOS SF20
SF 36
Deglutition QLQ OES24 Deglutition disturbances
(DAUG 32)
Depression HADS Depression-dejection
(POMS)
General health SF 36 Health perceptions
(MOS SF20)
a‘similar’ = one or more identical word.
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the approach to including PROs [86-89]. In rheumatoid
arthritis, for example, the initial American College of
Rheumatology (ACR) core set was developed by a com-
mittee of experts (16 professionals in rheumatoid arth-
ritis trials, health services research and biostatistics)
who reviewed the literature on the validity of trial outcomes
(for example, sensitivity to change or how well it predicted/
correlated with a definite clinical change) and used a nom-
inal group process to recommend and reach consensus on
a list of core outcomes. The list was presented and fina-
lised at a specialist international conference (OMERACT:
Outcome Measures for Rheumatology in Clinical Trials)
and contained both clinical and PROs, although patients
were not involved in the consensus process. Outcomes
were specific (for example, number of swollen joints) or
more general domains (for example, functional status),
with recommendations on how to measure the outcomes
decided later [86]. Subsequent OMERACTconference dis-
cussions and workshops deliberately involved patients and
Table 4 Categorised PRO health domains showing number of items in existing PROMs assessing each domain
Specific measures for gastrointestinal disease Cancer specific measures Generic
measures
PRO domain EQOL FACT-E GERD-
HRQL
GIQLI DAUGS 32 LAGS QLQ-
OG25
QLQ-
OES18
QLQ-
OES24
Adapted
RSCLa
Adapted
RSCLb
RSCL PNPC QLQ-
C30
QLQ-
C36
WOCS OS
f-20
PAIS POMS SF 36 HADS Frequency
assessed in
PROMs (total
number of
items)
Disease specific
Pain/pain-related
swallowing
3 1 1 2 1 3 3 3 5 6 1 2 1 2 15 (35)
Appetite/eating/
taste
4 3 4 5 1 6 4 4 3 1 1 1 1 13 (38)
Fatigue 1 1 2 1 1 2 1 3 3 15 4 11 (34)
Dysphagia/
swallowing saliva
1 4 1 1 2 1 4 4 4 2 1 11 (25)
Regurgitation/
vomiting
1 1 5 1 1 1 1 2 1 1 1 11 (16)
Reflux/heartburn 1 6 1 2 1 1 1 1 1 1 10 (16)
Nausea 1 1 1 1 1 1 1 1 1 9 (9)
Belching/
bloating/gas
1 1 4 3 1 1 1 7 (12)
Diarrhoea/frequent
bowel movements
5 2 1 1 1 1 1 7 (12)
Cough 1 1 1 1 1 1 1 7 (7)
Choking 1 1 1 1 1 1 1 7 (7)
Dry mouth 1 1 1 1 1 1 6 (6)
Breathing 1 1 1 1 1 1 6 (6)
Weight 1 1 1 1 1 1 6 (6)
Communication/
speech difficulties
2 1 1 1 1 5 (6)
Eating - social
impact
1 1 1 1 1 5 (5)
Sexual function 1 1 1 6 4 (9)
Constipation 1 1 1 1 4 (4)
Hair loss 1 1 1 1 4 (4)
Body image 1 1 1 1 4 (4)
Dizziness/
dumping
5 2 1 3 (8)
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Table 4 Categorised PRO health domains showing number of items in existing PROMs assessing each domain (Continu )
Generic
Emotional function 2 8 6 3 2 3 7 5 7 19 4 8 4 6 43 5 14 18 (151)
Role physical/ADLs 2 2 1 2 8 8 8 9 3 4 4 5 13 (59)
Physical function 2 3 1 25 3 4 4 6 1 9 11 (63)
Social function 1 7 1 19 2 2 17 2 9 (52)
Generic health 1 1 1 1 2 6 7 (17)
Sleep 1 1 1 1 1 1 1 7 (7)
Global QOL 1 1 4 1 1 2 6 (10)
Cognition 1 3 2 1 7 5 (14)
Role emotional 2 4 2 3 4 (11)
Financial issues 5 1 1 1 4 (8)
Spiritual issues 2 1 (2)
aAdapted RSCL - de Boer study.
bAdapted RCSL - van Knippenberg study
ADLs: Activities of daily life.
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Table 5 Selected categorised health domains and example PROM items mapped to these domains
PRO domain Example items (origin PROM)
Emotional function Did you feel tense? (QLQ-C30)
I feel sad (FACT-E)
How often in the past two weeks have you felt fearful of cancer recurrence? (EQOL)
Role physical/ADLs Has your illness interfered with your ability to do your job? (PAIS)
If you take medicine, does this affect your daily life? (GERD-HRQL)
Does your health now limit you in bathing or dressing yourself? (SF 36)
Physical function Because of your illness, how much physical strength have you lost? (GIQLI)
Did you have any trouble taking a long walk? (QLQ-C30)
I am forced to spend time in bed (FACT-E)
Social function How limited have you been in the past two weeks visiting friends or relatives? (EQOL)
To what extent have your personal relations with people close to you worsened because of your illness? (GIQLI)
Are you still as interested in your leisure time activities and hobbies as you were prior to your illness? (PAIS)
Generic health How often during the past two weeks have you felt unwell (GIQLI)
How would you rate your overall health during the past week? (QLQ-C30)
I seem to get sick a little easier than other people (SF 36)
ADLs: Activities of daily life.
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and continued work using interviews with patients,
identified further important PROs [5]. This led to the
development of a ‘patient core set’ of disease-specific
and global outcome domains solely derived from patient
opinion to complement the professional ACR core set
[88]. Our current study methodology ensures that the
patient perspective and relevant PROs inform the de-
velopment of a core set of outcome domains from an
early stage, because it examines the content of validated
PROMs which are developed with significant patient in-
volvement. The identified PRO domains will be prioritised
using a Delphi method to reach consensus on the import-
ant to include in the core outcome set, alongside clinical
outcomes [1], and is the focus of future work. Patients,
surgeons and clinical nurse specialists will be surveyed to
ensure the opinions of all key stakeholders are sought, a
recommended approach by the COMET (Core Outcome
Measures in Effectiveness Trials) initiative [4].
This study included a detailed systematic search to
identify PROs measured in oesophageal cancer studies
and used rigourous methodology to identify health domains,
however, it does have weaknesses. The categorisation of
question items into health domains was performed by two
experts and independently checked by other members
of the research team, including a patient advocate, but
it is possible that others may have categorised items
differently. Inter-rater reliability statistics could have
been recorded to describe agreement between the experts
when categorising items. Future work therefore is needed
to standardised and validate this method. In addition,
presentation of the methodology to a greater numberof patients or patient representatives could strengthen the
robustness and reliability of the categorisation process.Conclusion
In summary, this study demonstrates there is diversity in
the PROMs selected to evaluate radical treatment for
oesophageal cancer. Within and between PROMs there
is a lack of clarity between named scales and items and
the underlying health domains being assessed meaning
data synthesis is limited. A methodology for identifying
important PRO health domains is proposed which can
be used to inform the development of a core set of health
domains. Following this it will be necessary to determine
accurate and efficient ways to measure these core domains,
drawing on items banks developed by initiatives such
as PROMIS (Patient Reported Outcomes Measurement
Information System) and COSMIN (Consensus-based
Standards for the selection of health status Measurement
Instruments) [91,92].Additional file
Additional file 1: Search strategy as applied to MEDLINE (OVID).Abbreviations
COS: Core outcome set; HRQL: Health-related quality of life; PRO: Patient-reported
outcome; PROM: Patient-reported outcome measure; RCT: Randomised
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